Fig. 1
Proportion of patients with ≥ 20% improvement in pain visual analog scale (VAS) score through week 104 (a) and proportion of patients with ≥ 20% improvement in pain VAS response (b)
Data are presented as LS mean change using MMRM from weeks 1-24, and observed data are presented from weeks 28-104 (shaded area); P values are calculated from a MMRM analysis (a). Observed data are presented; P values are calculated from Fisher’s exact test (b)
1Number of patients originally randomized to each treatment group. *P < 0.0001; †P < 0.001; ‡P < 0.05 §P < 0.01 versus placebo
LS, least squares; MMRM, mixed-effect model for repeated measures; PBO, placebo; s.c., subcutaneous; SEC, secukinumab
